A 0 1 0 1 O
negative 2 10 2 10 B-pregnancy
urine 11 16 11 16 I-pregnancy
pregnancy 17 26 17 26 I-pregnancy
test 27 31 27 31 O
is 32 34 32 34 O
required 35 43 35 43 O
within 44 50 44 50 O
1 51 52 51 52 B-upper_bound
week 53 57 53 57 I-upper_bound
for 58 61 58 61 O
all 62 65 62 65 O
women 66 71 66 71 B-gender
of 72 74 72 74 O
childbearing 75 87 75 87 O
potential 88 97 88 97 O
prior 98 103 98 103 O
to 104 106 104 106 O
enrolling 107 116 107 116 O
on 117 119 117 119 O
this 120 124 120 124 O
trial 125 130 125 130 O

Adequate 0 8 131 139 O
organ 9 14 140 145 O
function 15 23 146 154 O
as 24 26 155 157 O
defined 27 34 158 165 O
below 35 40 166 171 O
: 40 41 171 172 O
liver 42 47 173 178 O
function 48 56 179 187 O
( 57 58 188 189 O
bilirubin 58 67 189 198 B-clinical_variable
< 68 69 199 200 O
/=2mg 69 74 200 205 O
/ 74 75 205 206 I-upper_bound
dL 75 77 206 208 I-upper_bound
, 77 78 208 209 O
AST 79 82 210 213 B-clinical_variable
and/or 83 89 214 220 O
ALT 90 93 221 224 B-clinical_variable
< 94 95 225 226 O
/=3 95 98 226 229 O
x 99 100 230 231 I-upper_bound
ULN- 101 105 232 236 I-upper_bound
or 106 108 237 239 O
< 109 110 240 241 O
5 110 111 241 242 B-upper_bound
x 112 113 243 244 I-upper_bound
ULN 114 117 245 248 I-upper_bound
if 118 120 249 251 O
related 121 128 252 259 O
to 129 131 260 262 O
leukemic 132 140 263 271 B-cancer
involvement 141 152 272 283 I-cancer
) 152 153 283 284 O
, 153 154 284 285 O
kidney 155 161 286 292 O
function 162 170 293 301 O
( 171 172 302 303 O
creatinine 172 182 303 313 B-clinical_variable
< 183 184 314 315 O
/=1.5 184 189 315 320 O
x 190 191 321 322 I-upper_bound
ULN 192 195 323 326 I-upper_bound
) 196 197 327 328 O
, 197 198 328 329 O
known 199 204 330 335 O
cardiac 205 212 336 343 B-clinical_variable
ejection 213 221 344 352 I-clinical_variable
fraction 222 230 353 361 I-clinical_variable
of 231 233 362 364 O
> 234 235 365 366 O
or 236 238 367 369 O
= 239 240 370 371 O
45 241 243 372 374 B-lower_bound
% 243 244 374 375 I-lower_bound
within 245 251 376 382 O
the 252 255 383 386 O
past 256 260 387 391 B-upper_bound
6 261 262 392 393 I-upper_bound
months 263 269 394 400 I-upper_bound

Age 0 3 401 404 B-age
< 4 5 405 406 O
/= 5 7 406 408 O
65 8 10 409 411 B-upper_bound
years 11 16 412 417 I-upper_bound

ECOG 0 4 418 422 B-clinical_variable
performance 5 16 423 434 I-clinical_variable
status 17 23 435 441 I-clinical_variable
of 24 26 442 444 O
< 27 28 445 446 O
/= 28 30 446 448 O
2 31 32 449 450 B-upper_bound

For 0 3 451 454 O
Frontline 4 13 455 464 O
cohort 14 20 465 471 O
: 20 21 471 472 O
No 22 24 473 475 O
prior 25 30 476 481 B-treatment
potentially 31 42 482 493 I-treatment
- 42 43 493 494 I-treatment
curative 43 51 494 502 I-treatment
therapy 52 59 503 510 I-treatment
for 60 63 511 514 O
leukemia 64 72 515 523 B-treatment
. 72 73 523 524 O
Prior 74 79 525 530 B-treatment
therapy 80 87 531 538 I-treatment
with 88 92 539 543 O
hydroxyurea 93 104 544 555 B-treatment
, 104 105 555 556 O
hematopoietic 106 119 557 570 B-treatment
growth 120 126 571 577 I-treatment
factors 127 134 578 585 I-treatment
, 134 135 585 586 O
azacytidine 136 147 587 598 B-treatment
, 147 148 598 599 O
decitabine 149 159 600 610 B-treatment
, 159 160 610 611 O
ATRA 161 165 612 616 B-treatment
, 165 166 616 617 O
or 167 169 618 620 O
a 170 171 621 622 O
total 172 177 623 628 O
dose 178 182 629 633 O
of 183 185 634 636 O
cytarabine 186 196 637 647 B-clinical_variable
up 197 199 648 650 O
to 200 202 651 653 O
2 203 204 654 655 B-upper_bound
g 204 205 655 656 I-upper_bound
( 206 207 657 658 O
for 207 210 658 661 O
emergency 211 220 662 671 O
use 221 224 672 675 O
for 225 228 676 679 O
stabilization 229 242 680 693 O
) 242 243 693 694 O
is 244 246 695 697 O
allowed 247 254 698 705 O
. 254 255 705 706 O
Patients 256 264 707 715 O
with 265 269 716 720 O
secondary 270 279 721 730 B-cancer
AMLwho 280 286 731 737 I-cancer
have 287 291 738 742 O
been 292 296 743 747 O
treated 297 304 748 755 O
for 305 308 756 759 O
their 309 314 760 765 O
antecedent 315 325 766 776 B-cancer
myeloid 326 333 777 784 I-cancer
neoplasm 334 342 785 793 I-cancer
will 343 347 794 798 O
be 348 350 799 801 O
enrolled 351 359 802 810 O
into 360 364 811 815 O
the 365 368 816 819 O
separate 369 377 820 828 O
Secondary 378 387 829 838 B-cancer
AML 388 391 839 842 I-cancer
cohort 392 398 843 849 O

For 0 3 850 853 O
Salvage 4 11 854 861 O
cohort 12 18 862 868 O
: 18 19 868 869 O
Patients 20 28 870 878 O
with 29 33 879 883 O
previously 34 44 884 894 O
treated 45 52 895 902 O
, 52 53 902 903 O
relapsed 54 62 904 912 B-cancer
or 63 65 913 915 I-cancer
refractory 66 76 916 926 I-cancer
AML 77 80 927 930 I-cancer
, 80 81 930 931 O
Acute 82 87 932 937 B-cancer
Biphenotypic 88 100 938 950 I-cancer
Leukemia 101 109 951 959 I-cancer
, 109 110 959 960 I-cancer
or 111 113 961 963 O
CML 114 117 964 967 B-cancer
in 118 120 968 970 O
Myeloid 121 128 971 978 O
Blast 129 134 979 984 O
Phase 135 140 985 990 O
are 141 144 991 994 O
eligible 145 153 995 1003 O

Men 0 3 1004 1007 B-gender
and 4 7 1008 1011 I-gender
women 8 13 1012 1017 I-gender
of 14 16 1018 1020 O
childbearing 17 29 1021 1033 O
potential 30 39 1034 1043 O
who 40 43 1044 1047 O
do 44 46 1048 1050 B-contraception_consent
not 47 50 1051 1054 I-contraception_consent
practice 51 59 1055 1063 I-contraception_consent
contraception 60 73 1064 1077 I-contraception_consent
. 73 74 1077 1078 O
Women 75 80 1079 1084 B-gender
of 81 83 1085 1087 O
childbearing 84 96 1088 1100 O
potential 97 106 1101 1110 O
and 107 110 1111 1114 O
men 111 114 1115 1118 O
must 115 119 1119 1123 O
agree 120 125 1124 1129 B-contraception_consent
to 126 128 1130 1132 I-contraception_consent
use 129 132 1133 1136 I-contraception_consent
contraception 133 146 1137 1150 I-contraception_consent
prior 147 152 1151 1156 O
to 153 155 1157 1159 O
study 156 161 1160 1165 O
entry 162 167 1166 1171 O
and 168 171 1172 1175 O
for 172 175 1176 1179 O
the 176 179 1180 1183 O
duration 180 188 1184 1192 O
of 189 191 1193 1195 O
study 192 197 1196 1201 O
participation 198 211 1202 1215 O

Patient 0 7 1216 1223 O
with 8 12 1224 1228 O
documented 13 23 1229 1239 O
hypersensitivity 24 40 1240 1256 O
to 41 43 1257 1259 O
any 44 47 1260 1263 O
of 48 50 1264 1266 O
the 51 54 1267 1270 O
components 55 65 1271 1281 O
of 66 68 1282 1284 O
the 69 72 1285 1288 O
chemotherapy 73 85 1289 1301 B-treatment
program 86 93 1302 1309 O

Patients 0 8 1310 1318 O
with 9 13 1319 1323 O
a 14 15 1324 1325 O
diagnosis 16 25 1326 1335 O
of 26 28 1336 1338 O
AML 29 32 1339 1342 B-cancer
, 32 33 1342 1343 O
Acute 34 39 1344 1349 B-cancer
Biphenotypic 40 52 1350 1362 I-cancer
Leukemia 53 61 1363 1371 I-cancer
, 61 62 1371 1372 O
or 63 65 1373 1375 O
high 66 70 1376 1380 O
risk 71 75 1381 1385 O
MDS 76 79 1386 1389 B-clinical_variable
( 80 81 1390 1391 O
> 81 82 1391 1392 O
/= 82 84 1392 1394 O
10 85 87 1395 1397 B-lower_bound
% 87 88 1397 1398 I-lower_bound
blasts 89 95 1399 1405 O
or 96 98 1406 1408 O
IPSS 99 103 1409 1413 B-clinical_variable
> 104 105 1414 1415 O
/= 105 107 1415 1417 O
intermediate-2 108 122 1418 1432 O
) 122 123 1432 1433 O
will 124 128 1434 1438 O
be 129 131 1439 1441 O
eligible 132 140 1442 1450 O
. 140 141 1450 1451 O
Patients 142 150 1452 1460 O
with 151 155 1461 1465 O
CML 156 159 1466 1469 B-cancer
in 160 162 1470 1472 O
Myeloid 163 170 1473 1480 O
Blast 171 176 1481 1486 O
Phase 177 182 1487 1492 O
are 183 186 1493 1496 O
also 187 191 1497 1501 O
eligible 192 200 1502 1510 O

Pregnant 0 8 1511 1519 B-pregnancy
women 9 14 1520 1525 B-gender
are 15 18 1526 1529 O
excluded 19 27 1530 1538 O
from 28 32 1539 1543 O
this 33 37 1544 1548 O
study 38 43 1549 1554 O
because 44 51 1555 1562 O
the 52 55 1563 1566 O
agents 56 62 1567 1573 O
used 63 67 1574 1578 O
in 68 70 1579 1581 O
this 71 75 1582 1586 O
study 76 81 1587 1592 O
have 82 86 1593 1597 O
the 87 90 1598 1601 O
potential 91 100 1602 1611 O
for 101 104 1612 1615 O
teratogenic 105 116 1616 1627 O
or 117 119 1628 1630 O
abortifacient 120 133 1631 1644 O
effects 134 141 1645 1652 O
. 141 142 1652 1653 O
Because 143 150 1654 1661 O
there 151 156 1662 1667 O
is 157 159 1668 1670 O
a 160 161 1671 1672 O
potential 162 171 1673 1682 O
risk 172 176 1683 1687 O
for 177 180 1688 1691 O
adverse 181 188 1692 1699 O
events 189 195 1700 1706 O
in 196 198 1707 1709 O
nursing 199 206 1710 1717 O
infants 207 214 1718 1725 O
secondary 215 224 1726 1735 O
to 225 227 1736 1738 O
treatment 228 237 1739 1748 B-treatment
of 238 240 1749 1751 O
the 241 244 1752 1755 O
mother 245 251 1756 1762 O
with 252 256 1763 1767 O
the 257 260 1768 1771 O
chemotherapy 261 273 1772 1784 B-treatment
agents 274 280 1785 1791 I-treatment
, 280 281 1791 1792 O
breastfeeding 282 295 1793 1806 O
should 296 302 1807 1813 O
also 303 307 1814 1818 O
be 308 310 1819 1821 O
avoided 311 318 1822 1829 O

Uncontrolled 0 12 1830 1842 O
intercurrent 13 25 1843 1855 B-chronic_disease
illness 26 33 1856 1863 I-chronic_disease
including 34 43 1864 1873 O
, 43 44 1873 1874 O
but 45 48 1875 1878 O
not 49 52 1879 1882 O
limited 53 60 1883 1890 O
to 61 63 1891 1893 O
active 64 70 1894 1900 B-chronic_disease
uncontrolled 71 83 1901 1913 I-chronic_disease
infection 84 93 1914 1923 I-chronic_disease
, 93 94 1923 1924 O
symptomatic 95 106 1925 1936 O
congestive 107 117 1937 1947 B-chronic_disease
heart 118 123 1948 1953 I-chronic_disease
failure 124 131 1954 1961 I-chronic_disease
( 132 133 1962 1963 O
NYHA 133 137 1963 1967 B-clinical_variable
Class 138 143 1968 1973 B-lower_bound
III 144 147 1974 1977 I-lower_bound
or 148 150 1978 1980 O
IV 151 153 1981 1983 B-upper_bound
) 153 154 1983 1984 O
, 154 155 1984 1985 O
unstable 156 164 1986 1994 B-chronic_disease
angina 165 171 1995 2001 I-chronic_disease
pectoris 172 180 2002 2010 I-chronic_disease
, 180 181 2010 2011 O
clinically 182 192 2012 2022 O
significant 193 204 2023 2034 O
cardiac 205 212 2035 2042 B-chronic_disease
arrhythmia 213 223 2043 2053 I-chronic_disease
, 223 224 2053 2054 O
or 225 227 2055 2057 O
psychiatric 228 239 2058 2069 B-chronic_disease
illness 240 247 2070 2077 I-chronic_disease
/ 247 248 2077 2078 O
social 248 254 2078 2084 B-chronic_disease
situations 255 265 2085 2095 I-chronic_disease
that 266 270 2096 2100 O
would 271 276 2101 2106 O
limit 277 282 2107 2112 O
compliance 283 293 2113 2123 O
with 294 298 2124 2128 O
study 299 304 2129 2134 O
requirements 305 317 2135 2147 O

